Evidence Connections

Follow the evidence beyond the paper.

Follow source-linked research projects, organizations, FDA application actions, compound targets and genetic studies.

Explore relationships stated by the original sources. Each number opens its exact collection—not a count of extra papers or proven treatments.

FDA application actionOctober 13, 2021

Pembrolizumab

Approved submission · SUPPL 122

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionOctober 13, 2021

Pembrolizumab

Approved submission · SUPPL 122

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionOctober 12, 2021

propofol

Approved submission · ORIG 1

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionOctober 8, 2021

Sildenafil citrate

Approved submission · SUPPL 3

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionSeptember 29, 2021

Decitabine

Approved submission · SUPPL 3

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionSeptember 29, 2021

Decitabine

Approved submission · SUPPL 4

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionSeptember 29, 2021

Decitabine

Approved submission · SUPPL 5

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionSeptember 29, 2021

Decitabine

Approved submission · SUPPL 1

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionSeptember 29, 2021

Decitabine

Approved submission · SUPPL 2

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionSeptember 29, 2021

Decitabine

Approved submission · SUPPL 3

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionSeptember 20, 2021

Decitabine

Approved submission · ORIG 1

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionSeptember 10, 2021

hydrochlorothiazide

Approved submission · SUPPL 80

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionSeptember 9, 2021

Cyclophosphamide

Approved submission · SUPPL 2

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionAugust 31, 2021

Pembrolizumab

Approved submission · SUPPL 117

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionAugust 31, 2021

Pembrolizumab

Approved submission · SUPPL 117

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionAugust 31, 2021

Pembrolizumab

Approved submission · SUPPL 118

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionAugust 31, 2021

Pembrolizumab

Approved submission · SUPPL 118

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionAugust 25, 2021

Everolimus

Approved submission · SUPPL 3

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionAugust 25, 2021

Cyclophosphamide

Approved submission · ORIG 1

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionAugust 17, 2021

Nystatin

Approved submission · ORIG 1

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionAugust 10, 2021

Nystatin

Approved submission · ORIG 1

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionAugust 10, 2021

Pembrolizumab

Approved submission · SUPPL 102

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionAugust 10, 2021

Pembrolizumab

Approved submission · SUPPL 102

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionAugust 9, 2021

Sirolimus

Approved submission · SUPPL 86

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →